UK expands prostate cancer screening trial to include more Black men

A new prostate cancer screening trial in the UK is expanding to include more Black men than previously, as scientists seek more accurate ways to detect cancer early. Blood tests alone are not sufficiently accurate for diagnosing prostate cancer. Researchers are looking for better screening methods.

The UK is expanding a clinical trial on prostate cancer screening to include more Black men than before. Scientists are seeking more accurate methods for early cancer detection, as the blood tests currently used are not sufficiently reliable for most men.

Prostate cancer screening is complex because the PSA blood test, which is often used, produces many false positives and false negatives. This means that many men undergo unnecessary further investigations, while in some cases cancer goes undetected. Black men are a higher-risk group for prostate cancer, which is why their inclusion in the trial is particularly important.

The trial is seeking better screening approaches that could combine different testing methods to increase diagnostic accuracy. The goal is to develop a more efficient screening programme that could save lives while reducing unnecessary medical procedures.